Mawson Graham - Australian Small-Cap Research
  • Home
  • About
  • Analyst Research
  • Guides
  • Online Platform
  • Contact
Access Research
  1. Home
  2. Research
  3. Reports
  4. ASX:XTE

ASX:XTE - Xtek Ltd Research

High growth potential via proprietary tech commercialisation and a reduced risk profile from contracted revenues.

XTE ASX Small Cap Research
Company Overview

Xtek is pursuing the commercialisation of its revolutionary carbon fibre composite technology, XTClave, for the global body armour market.

Release Date (3 years ago)
  •   March 6th, 2019
All XTE Reports
  • October 31st, 2019
  • July 18th, 2019
  • March 6th, 2019
Report Includes
  • Recent events
  • Investment highlights
  • Analyst's view
  • Consensus targets
  • More...
Analyst
SmallCapInsider
 Research
Download Report

We believe that XTEK warrants further investigation by investors with a high tolerance for risk that are seeking growth opportunities. XTEK has viable growth potential via the commercialisation of their 100% owned proprietary products XTCLAVE and XTATLAS. However, we note that the Company has also reported two years of net profit after tax for FY2016/2017 and FY2017/20188. Consequently, we believe that XTEK also has a relatively reduced risk profile in comparison to other listed small growth companies of similar market capitalisations that have a history of negative earnings.  

We believe that the recent spare parts contract win on the 22nd November 2018 is validation that XTEK is also likely performing to the ADF’s expectations. This contract win combined with their existing repair facilities situated in Canberra means XTEK is likely to maintain the repair component of the $101m SUAS budget that was announced by the Department of Defence on the 1st June 2017. Consequently, these revenue streams will likely continue to underpin XTEK’s relatively stronger earnings position. XTEK have also flagged the possibility of acquiring domestic small, profitable and innovative technology companies, which we also view a positive to XTEK’s longer-term earnings potential if done prudently.

Download Report
Mawson Graham - ASX Research

1300 131 551 [email protected]

Mawson Graham
Level 33, 264 George St
New South Wales 2000
Australia

Connect with us:

Mawson Graham Pty Ltd (ABN 53 631 737 650) is Corporate Authorised Rep (CAR) of Vested Equities Pty Ltd (ABN 54 601 621 390) Australian Financial Services (AFS) Licence 478987. The content on this website is for general information purposes only and is not intended to reflect any recommendations or financial advice. The information on this site has been prepared without taking into account your objectives, financial situation or needs. For this reason, you should consider the appropriateness of the advice or recommendation in light of your own personal circumstances, relevant risk factors, the nature and extent of your risk of loss, as well as the legal and accounting consequences before acting making an investment or trading decision regarding any Financial Product mentioned herein. While it is believed that all information sourced and contained on this website to be accurate at the time of publication, liability for any errors, omissions, accuracy or completeness of the information (except any statutory liability which cannot be excluded) is specifically excluded by Mawson Graham, its associates, officers, directors, employees and agents. Past performance is not a reliable indicator of future performance. Important Disclosure: Mawson Graham Pty Ltd, its directors, associates and employees advise that they may hold securities, may have an interest in and/or earn brokerage, corporate and/or investor relations fees, and other benefits or advantages, either directly or indirectly from client transactions arising from any information mentioned on this website and in documents published to this website. Directors, associates and employees of Mawson Graham Pty Ltd from time to time may hold shares in the security/securities mentioned on this website and in documents published on this website and, therefore, may benefit from any increase in the price of those securities.

© 2022 Mawson Graham All Rights Reserved
Terms Privacy FSG Transparency